Results 21 to 30 of about 27,201 (202)
Frontiers in Oncology, 2022 BackgroundRecent breakthroughs in cholangiocarcinoma (CCA) genomics have led to the discovery of many unique identifying mutations, of which HER2 has been found to be overexpressed specifically in cases of extrahepatic CCA.
Zhiqing Bai +9 more
doaj +1 more source
Biosensors, 2023 Breast cancer (BC) is one of the most common types of cancer disease worldwide and it accounts for thousands of deaths annually. Lapatinib is among the preferred drugs for the treatment of breast cancer. Possible drug toxicity effects of lapatinib can be
Jaymi Leigh January +7 more
doaj +1 more source
Breast Cancer Research, 2014 Introduction Src tyrosine kinase overactivation has been correlated with a poor response to human epidermal growth factor receptor 2 (HER2) inhibitors in breast cancer.
Luigi Formisano +14 more
doaj +1 more source
Frontiers in Oncology, 2020 BackgroundIntracranial activity of lapatinib has been demonstrated in several studies in patients with human epidermal growth factor receptor-2 positive breast cancers (HER-2+ BC).
Muhammad Khan +6 more
doaj +1 more source
, 2023 Significantly affected proteins by lapatinib and dasatinib in combination vs lapatinib alone in HER2+ tumors.
Gunhild Mari Mælandsmo (7954913) +9 more
core +1 more source
Lapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffolds. [PDF]
PLoS ONE, 2013 Human African trypanosomiasis is caused by the eukaryotic microbe Trypanosoma brucei. To discover new drugs against the disease, one may use drugs in the clinic for other indications whose chemical scaffolds can be optimized via a medicinal chemistry ...
Samiksha Katiyar +7 more
doaj +1 more source
European Journal of Breast Health, 2015 Lapatinib is an effective drug in HER2-positive breast cancer. We present a case with successful treatment of lapatinib in brain metastasis of HER2+ breast cancer. Forty-eight years old woman was admitted our clinic with early breast cancer.
Bülent Karagöz +6 more
doaj +1 more source
Amygdalin may potentiate the effects of lapatinib on SK-BR-3 cancer cell death through increasing Bax expression [PDF]
مجله علمی دانشگاه علوم پزشکی کردستان, 2023 Background and Aim: : HER-2 Positive breast cancer is one of the aggressive types of cancer and is resistant to chemotherapy drugs such as lapatinib .Amygdalin is a natural compound found in the seeds of fruits such as apricot, peache, apple and almond ...
Bahman Moradi poodeh
doaj
Mechanisms of resistance to lapatinib in HER2 positive breast cancer [PDF]
, 2012 Lapatinib is a tyrosine kinase inhibitor of HER2 which blocks downstream signaling pathways in HER2 positive breast cancer cell lines, tumor xenografts and HER2 positive breast cancer patients.
McDermott, Martina
core +1 more source
Biomedicines, 2019 Lapatinib is an orally administered, dual ErbB1/ErbB2 tyrosine kinase inhibitor (TKI). It is effective in ErbB2 + ve breast cancer treatment. However, lapatinib is associated with diarrhoea with an incidence of 47−75%.
Wan Nor I′zzah Wan Mohamad Zain +3 more
doaj +1 more source